David Knopman (Mayo Clinic via YouTube)

A sec­ond ad­comm mem­ber aban­dons his post in af­ter­math of con­tro­ver­sial ad­u­canum­ab de­ci­sion

As the fall­out from the FDA’s ap­proval of Alzheimer’s med ad­u­canum­ab grows, a sec­ond mem­ber of the ad­comm over­see­ing that drug’s re­view has walked away. But even with two ex­perts now hav­ing re­signed from that com­mit­tee in protest, is there enough broad-lev­el out­rage to pre­vent an­oth­er ad­u­canum­ab from get­ting ap­proved?

The FDA on Wednes­day lost an­oth­er mem­ber of its Pe­riph­er­al and Cen­tral Ner­vous Sys­tem Drugs Ad­vi­so­ry Com­mit­tee as Mayo Clin­ic neu­rol­o­gist David Knop­man hit the ex­it over the agency’s de­ci­sion to ap­prove Bio­gen’s Alzheimer’s drug Aduhelm de­spite the com­mit­tee’s near-unan­i­mous vote against it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.